10 assets in Drug-Induced Dyskinesia

Therapeutic assets addressing Drug-Induced Dyskinesia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Levodopa Drug-Induced Dyskinesia	Sumitomo Pharma Co., Ltd.	P4	A (80)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Drug-Induced Dyskinesia	PharmaTher Inc.	P2	B (60)
Befiradol Drug-Induced Dyskinesia	Neurolixis SAS	P2	B (57)
cpl500036 - high dose Drug-Induced Dyskinesia	Celon Pharma SA	P2	B (57)
cpl500036 - low dose Drug-Induced Dyskinesia	Celon Pharma SA	P2	B (57)
jm-010 Drug-Induced Dyskinesia	Contera Pharma A/S	P2	CCC (54)
av-101 Drug-Induced Dyskinesia	VistaGen Therapeutics, Inc.	P2	CCC (53)
Midazolam Drug-Induced Dyskinesia	PharmaTher Inc.	P2	CCC (53)
Dsp-9632P Drug-Induced Dyskinesia	Sumitomo Pharma Co., Ltd.	P1	CC (47)
Dipraglurant Drug-Induced Dyskinesia	Addex Pharma S.A.	P2/3	C (38)